Key result
Apixaban, rivaroxaban, and dabigatran cost $93,063, $111,465, and $140,557 per additional QALY gained compared with warfarin, making apixaban optimal at a $100,000/QALY threshold.
Why the study?
Are novel oral anticoagulants (dabigatran, apixaban, rivaroxaban) cost-effective compared to warfarin in patients with newly diagnosed atrial fibrillation?
Are novel oral anticoagulants (dabigatran, apixaban, rivaroxaban) cost-effective compared to warfarin in patients with newly diagnosed atrial fibrillation?
Apixaban appears to be the optimal anticoagulation strategy at a $100,000/QALY threshold, but this finding is highly sensitive to efficacy and cost assumptions, suggesting NOACs may not consistently represent good value for money compared to warfarin.
Answers are grounded in this paper and cite their sources.
Apixaban may be preferred at a $100,000/QALY threshold; leaves open whether NOACs consistently offer value versus warfarin given sensitivity to assumptions.
BACKGROUND: New anticoagulants may improve health outcomes in patients with atrial fibrillation, but it is unclear whether their use is cost-effective. METHODS AND RESULTS: A Markov state transition was created to compare 4 therapies: dabigatran 150 mg BID, apixaban 5 mg BID, rivaroxaban 20 mg QD, and warfarin therapy. The population included those with newly diagnosed atrial fibrillation who were eligible for treatment with warfarin. Compared with warfarin, apixaban, rivaroxaban, and dabigatran, costs were $93 063, $111 465, and $140 557 per additional quality-adjusted life year gained, respectively. At a threshold of $100 000 per quality-adjusted life year, apixaban provided the greatest absolute benefit while still being cost-effective, although warfarin would be superior if apixaban was 2% less effective than expected. Although apixaban was the optimal strategy in our base case, in probabilistic sensitivity analysis, warfarin was optimal in an equal number of iterations at a cost-effectiveness threshold of $100 000 per quality-adjusted life year. CONCLUSIONS: While at a standard cost-effectiveness threshold of $100 000 per quality-adjusted life year, apixaban seems to be the optimal anticoagulation strategy; this finding is sensitive to assumptions about its efficacy and cost. In sensitivity analysis, warfarin seems to be the optimal choice in an equal number of simulations. As a result, although all the novel oral anticoagulants produce greater quality-adjusted life expectancy than warfarin, they may not represent good value for money.
No takes yet. Share an insight, caveat, or question.
Canestaro et al. (2013) studied newly diagnosed atrial fibrillation. apixaban, rivaroxaban, and dabigatran vs. warfarin was evaluated on cost per additional quality-adjusted life year gained. Apixaban, rivaroxaban, and dabigatran cost $93,063, $111,465, and $140,557 per additional QALY gained compared with warfarin, making apixaban optimal at a $100,000/QALY threshold.
Synapse has enriched 10 related papers. Consider them for comparative context: